A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

NCT07198087 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Central Nervous System Lymphoma (PCNSL)

Interventions

DRUG: Tirabrutinib

Sponsor

Ono Pharmaceutical Co., Ltd.